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Abstract: Background and objectives: Inflammatory bowel disease (IBD) is associated with an increased
risk of developing colorectal cancer as well as some extra-intestinal tumors, but there are still limited
data about the risk of prostate cancer (PC). To analyze if there is an increased risk of PC in patients
affected by IBD, we performed a systematic review with meta-analysis. Materials and Methods:
A Pubmed search of all studies comparing standardized incidence ratio (SIR) or odds ratio (OR)
or relative risks (RR) of PC between IBD and non IBD groups, published until March 2020 was
conducted. The study protocol was registered on PROSPERO. Twelve studies, mostly population
studies, were included. The quality score of these studies, evaluated by the Newcastle–Ottawa
Scale, was 7. The heterogeneity was high among the studies in which ulcerative colitis (UC) was
considered separate from Crohn’s disease (CD) and in the studies that considered UC and CD together
(“IBD-studies”), while it was low in the studies which considered CD separate from UC. Results:
The relative risk of developing PC was 1.71 (95% confidence interval [CI] 1.16–2.51, p = 0.007) in
IBD, 1.10 (95%CI 0.98–1.25, p = 0.116) in CD, and 1.22 (95%CI 0.98–1.51, p = 0.07) in UC. Conclusions:
Patients with IBD appear to have a slightly increased risk of PC compared to the general population.
Keywords: Crohn’s disease; ulcerative colitis; urological cancer; screening; systematic review
1. Introduction
Inflammatory bowel disease (IBD) is characterized by a chronic idiopathic gastrointestinal
inflammation due to a dysregulated immune response. Based on clinical, histopathological,
and endoscopic features, IBD can be differentiated in Crohn’s Disease (CD) and Ulcerative Colitis
(UC) [1]. Although it is reported that the pathogenesis of IBD originates from a dysregulated interaction
between genetic and environmental factors, the precise etiology is still unknown [2,3]. Patients may
also present extra-intestinal manifestations, such as arthritis, erythema nodosum, uveitis, or primary
sclerosing cholangitis [4]. It is estimated that 1.5 million Americans and 2.2 million people in Europe
are affected by IBD, and several studies have identified an increase in incidence, particularly in newly
industrialized countries [5,6].
Chronic inflammation is a well-known risk factor for cancer development, and in the literature, it is
widely acknowledged that IBD is associated with a higher risk of intestinal cancers, such as colorectal
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cancer or small bowel adenocarcinoma [7,8]. Several studies showed that IBD may also be linked to
several extra-intestinal neoplasms, such as lymphoma, melanoma, and cholangiocarcinoma [9,10].
Prostate cancer (PC) is the second most frequent malignancy in men worldwide, but only limited
and controversial data on the risk of PC in IBD patients are available [11]. Indeed, some studies pointed
out an increased risk of PC in IBD, while others did not confirm this conclusion [12,13].
In the present study, we conducted a systematic review with meta-analysis aimed at analyzing
the association between IBD and PC.
2. Materials and Methods
This systematic review with meta-analysis was conducted according to the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [14]. The study protocol was
registered on PROSPERO.
Articles published in English about risks of PC in patients with IBD were identified through
PubMed (“All databases”) searches using the terms “(inflammatory bowel disease [Title] OR Crohn’s
Disease [Title] OR Ulcerative Colitis [Title]) AND prostate [Title] AND cancer [Title]”. The final date of
the search was March 30, 2020.
Reference lists from published articles were also employed, such as citing articles on PubMed
Central. Titles of these publications and their abstracts were scanned in order to eliminate duplicates
and irrelevant articles. The inclusion criteria were: (1) studies comparing the incidence of PC between
a group of IBD patients and those without IBD or subjects belonging to the general population;
(2) studies reporting standardized incidence ratio (SIR) or odds ratio (OR) or relative risks (RR) and the
corresponding 95% confidence intervals (CI); (3) whatever the sample was. The exclusion criteria were:
(1) studies which did not estimate the association between IBD and PC risk; (2) studies which did not
report the number of PC in the two cohorts; (3) reviews; (4) case reports; (5) meta-analyses.
Two authors (D.G.R. and E.C.) independently reviewed titles and abstracts of references retrieved
from the literature search and selected potentially relevant studies. The full-text versions of selected
studies were then assessed by the two authors to determine whether the inclusion criteria were satisfied.
Differences in opinion were solved by discussion until consensus was reached. If an agreement failed
to be reached, a third author (G.M.S.) was consulted.
2.1. Statistical Analysis
The following information was collected: first author, country, publication year, number of patients
included, numbers of cancers observed in the cohort, expected numbers in a matched background
population, SIRs or OR or RRs, and 95%CI.
Cochran’s Q and I2 statistics were used to estimate heterogeneity across studies. When assessing
heterogeneity (Q-test’s p < 0.05, I2 > 50%), a random-effect model was used (this model tends to give
a more conservative estimate, i.e., with wider confidence interval), otherwise a fixed-effect model
was employed.
p value < 0.05 was treated as statistically significant. Statistical analyses were conducted using
Med Calc® version 18.9.1 software (Ostend, Belgium).
2.2. Quality Assessment and Risk of Bias
The Newcastle–Ottawa Scale (NOS) was used to evaluate the quality of the included studies.
The NOS is based on a “star system” and judges study quality according to three perspectives: selection
of the study groups, comparability of the groups, and ascertainment of the outcome of interest.
The average of quality score was 7 for all the included studies (Table 1).
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Table 1. Newcastle-Ottawa Scale for the risk of bias assessment of included studies.
Studies Selection Comparability Outcome Overall Quality Score
Cohort study
Karlen (1999) [15] 4 0 1 5
Bernstein (2001) [16] 4 1 3 8
Whinter (2004) [17] 4 0 2 6
Hemminki (2008) [18] 4 1 2 7
Hemminki (2009) [19] 4 1 2 7
Jussila (2013) [13] 4 0 3 7
Kappelman (2014) [10] 4 1 3 8
Wilson (2016) [20] 4 2 2 8
Jung (2017) [21] 4 1 1 6
So (2017) [22] 4 2 3 9
Case-control study
Burns (2018) [12] 4 2 2 8
Mosher (2018) [23] 4 0 2 6
To identify publication bias, funnel plots were created and visually evaluated. In the absence of
publication bias, the distribution of effect estimates in the funnel plot resembles a symmetrical inverted
funnel, whereas heterogeneity, publication bias, or chance lead to an asymmetrical funnel plot [24].
3. Results
3.1. Studies Selected
We identified 150 studies satisfying the search terms. After screening titles and abstracts, 12 of
these underwent full-text review. During this process, four papers were excluded as one study was
a case-report, one study did not report the exact number of patients with PC, and two studies did not
have a comparison with a non-IBD population. By reviewing the lists of references from the retrieved
articles, four other articles were included. Twelve studies were finally included, 10 of them were cohort
studies, while two had a case-control design. Among these studies, six evaluated the risk of PC in
both CD and UC, three evaluated only the correlation between UC and PC, one explored only the
correlation between CD and PC, and two referred to IBD patients, without differentiating between the
two types [10,12,13,15–23].
The flow diagram about the studies’ identification, screening, eligibility, and the number of
included studies is reported in Figure 1.
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3.2. Prostate Cancer in IBD Patients
Among the eight studies evaluating PC risk in IBD (Table 2), three did not show any difference of
risk of PC in IBD. The first study was made by Bernstein et al., who investigated the incidence rate
ratio (IRR) of various cancers between a cohort of 5529 IBD patients and the general population of
Manitoba County. In this study, the IRR for PC was 0.86 (95%IC: 0.57–1.28) [16]. A similar result was
obtained by Wilson et al., who compared the risk of cancer between a cohort of 19,647 patients with
IBD and an equivalent cohort of subjects without IBD, using data from the clinical practice research
datalink (UK), and described a SIR for PC of 1.18 (95%IC 0.85–1.63) [20]. The same conclusion was
reached by Jussila et al., who in a nation-wide study in Finland assessed the risk of many malignancies
among patients with IBD, reporting a SIR for PC of 0.84 (95%IC 0.73–0.97) [13].
Five studies, instead, evidenced an opposite scenario, pointing out an increased risk of PC in
patients with IBD. Kappelman et al., in a Danish population-based study, reported an SIR for PC
of 1.21 (IC 1.08–1.35) [10]. The same result was obtained in two Asian studies, by So et al. and
Jung et al., in the Hong-Kong and South-Korean general population, respectively, which showed a SIR
for PC of 2.03 (95%IC 1.02–4.06) and a SIR for PC of 3.06 (95%IC 1.95–4.80) [21,22]. Moreover, the two
case-controls studies showed an increased risk of PC in IBD. Burns et al., by comparing the risk of PC
between 1033 patients with IBD and 9306 patients without IBD, who presented at clinics within the
Northwestern medicine network (USA), found the highest RR of PC (RR 9.32; 95%IC 5.62–15.46) in IBD
patients [12]. Finally, Mosher et al., analyzed 2080 patients affected by IBD and 271,898 controls from
the Department of Veteran Affairs in North Texas, and found a RR for PC of 1.71 (95%IC 0.97–3.02) in
IBD patients [23].
The meta-analysis indicated that IBD was associated with a RR for PC of 1.71 (IC 1.16–2.51,
p = 0.007). As a high heterogeneity was detected (Q test, p < 0.0001; I2 = 93.62%), a random effects
model was used (Figure 2).
Table 2. Characteristics of the studies about IBD patients included in the meta-analysis.
Author Location Region DataSource Year
PC/Patients
with IBD
PC/Control
Population RR 95%CI
Bernstein et al. [16] Canada Manitoba C.R. 2001 26/5526 6293/1,151,000 0.86 0.59–1.26
Jussila et al. [13] Finland Finland C.R. 2013 176/21,964 51,045/5,351,000 0.84 0.73–0.97
Kappelman et al. [10] Denmark Denmark C.R. 2014 316/42,717 33,960/5,554,844 1.21 1.08–1.35
Wilson et al. [20] UK UK CPRD 2016 79/19,647 67/19,647 1.18 0.85–1.63
Jung et al. [21] Korea Korea HIRA-d 2017 19/15,291 20,607/50,750,000 3.06 1.95–4.80
So et al. [22] H.K. H.K. IBD-d 2018 8/2621 11,115/7,392,000 2.03 1.03–4.06
Mosher et al. [23] USA North Texas C.C. 2018 12/2080 916/271,898 1.71 0.97–3.02
Burns et al. [12] USA Northwestern NMADR 2018 30/1033 29/9306 9.32 5.62–15.46
H.K.: Hong Kong; USA: United States of America; C.R.: cancer register; CPRD: clinical practice research Datalink;
HIRA-d: Health Insurance and Review Agency database; PC: prostate cancer; IBD: inflammatory bowel disease;
C.C.: case-control; NMADR: Northwestern medicine administrative dataset repository; RR: relative risk; CI:
confidence intervals.
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3.3. Prostate Cancer in CD Patients
We found six studies comparing the incidence of PC in CD patients with that of the general
population (Table 3). Only one study, performed by Hemminki et al. in a nation-wide population
study from Sweden with a cohort of 21,788 CD patients, showed a significant SIR for PC of 1.19 (95%IC
1.02–1.40) [19].
Table 3. Characteristics of the studies about CD patients included in the meta-analysis.
Author Location Region Datasource Year
PC/Patients
with CD
PC/Control
Population RR 95%CI
Bernstein et al. [16] Canada Manitoba C.R. 2001 7/2857 4338/1,151,000 0.65 0.31–1.36
Hemminki et al. [19] Sweden Sweden C.R. 2009 152/21,788 52,621/8,976,000 1.20 1.02–1.40
Jussila et al. [13] Finland Finland C.R. 2013 26/5315 33,134/5,351,000 0.79 0.54–1.14
Kappelman et al. [10] Denmark Denmark C.R. 2014 58/13,756 19,518/5,554,844 1.20 0.93–1.55
Wilson et al. [20] UK UK CPRD 2016 79/19,647 67/19,647 1.18 0.85–1.63
Jung et al. [21] Korea Korea HIRA-d 2017 19/15,291 20,607/50,750,000 3.06 1.95–4.80
C.R.: cancer register; CPRD: clinical practice research Datalink; HIRA-d: Health Insurance and Review Agency
database; PC: prostate cancer; CD: Crohn’s disease; RR: relative risk; CI: confidence intervals.
The meta-analysis indicated that CD was associated with a RR for PC of 1.10 (95%IC 0.98–1.25,
p = 0.12). As a low heterogeneity was detected (Q test, p = 0.29; I2 = 19.05%), a fixed effects model was
used (Figure 3).
Medicina 2020, 56, x FOR PEER REVIEW 9 of 10 
 
Table 3. Characteristics of the studies about CD patients included in the meta-analysis. 
Author Location Region Data source Year PC/Patients with CD PC/Control Population RR 95%CI 
Bernstein et al. [16] Canada Manitoba C.R. 2001 7/2,857 4,338/1,151,000 0.65 0.31–1.36 
Hemminki et al. [19] Sweden Sweden C.R. 2009 152 21,788 52,621/8,976,00  1.20 1.02–1.40 
Jussila et al. [13] Finland Finland C.R. 2013 26/5,315 33,134/5,351,000 0.79 0.54–1.14 
Kappelman et al. [10] Denmark Denmark C.R. 2014 58/13,756 19,518/5,554,844 1.20 0.93–1.55 
Wilson et al. [20] UK UK CPRD 2016 79/19,647 67/19,647 1.18 0.85–1.63 
Jung et al. [21] Korea Korea HIRA-d 2017 19/15,291 20,607/50,750,000 3.06 1.95–4.80 
C.R.: cancer register; CPRD: clinical practice research Datalink; HIRA-d: Health Insurance and Review 
Agency database; PC: prostate cancer; CD: Crohn’s disease; RR: relative risk; CI: confidence intervals. 
 
 
(a) 
 
 
(b) 
Figure 3. (a) Forest plot of RR of PC in Crohn’s disease (CD); (b) Begg’s funnel plot for CD. 
3.4. Prostate Cancer in UC Patients 
Nine studies reporting PC incidence in UC patients were analyzed (Table 4). Five of these did 
not describe any significant difference between subjects with UC and the general population, while 
four of these pointed out to the opposite scenario. Karlén et al., in a population study conducted in 
Stockholm County, showed an SIR of 0.70 (95%IC 0.33–1.47) for PC [15]. In a similar population study, 
conducted in Copenhagen County, Winther et al. reported an SIR for PC of 0.74 (IC 0.28–1.97) [17]. 
Hemminki et al., instead, by evaluating the incidence of PC in 27.606 patients with UC compared to 
the Swedish general population, found an SIR for PC of 1.14 (95%IC 1.01–1.28) [18]. 
The meta-analysis indicated that UC was associated with a RR for PC of 1.22 (IC 0.98–1.51, p = 
0.07). High heterogeneity was present (Q test, p < 0.0001; I2 = 81.86%); thus, a random effects model 
was used (Figure 4). 
  
Figure 3. (a) Forest plot of RR of PC in Crohn’s disease (CD); (b) Begg’s funnel plot for CD.
3.4. Prostate Cancer in UC Patients
Nine studies reporting PC incidence in UC patients were analyzed (Table 4). Five of these did
not describe any significant difference between subjects with UC and the general population, while
four of these pointed out to the opposite scenario. Karlén et al., in a population study conducted in
Stockholm County, showed an SIR of 0.70 (95%IC 0.33–1.47) for PC [15]. In a similar population study,
conducted in Copenhagen County, Winther et al. reported an SIR for PC of 0.74 (IC 0.28–1.97) [17].
Hemminki et al., instead, by evaluating the incidence of PC in 27,606 patients with UC compared to
the Swedish general population, found an SIR for PC of 1.14 (95%IC 1.01–1.28) [18].
The meta-analysis indicated that UC was associated with a RR for PC of 1.22 (IC 0.98–1.51,
p = 0.07). High heterogeneity was present (Q test, p < 0.0001; I2 = 81.86%); thus, a random effects
model was used (Figure 4).
Medicina 2020, 56, 285 6 of 9
Table 4. Characteristics of the studies about UC patients included in the meta-analysis.
Author Year Location Region DataSource
n. of
PC/Patients
with UC
n. of
PC/Control
Population
RR 95%CI
Karlèn et al. [15] 1999 Sweden Stockholm C.R. 7/1547 11,526/1,783,000 0.70 0.33–1.47
Bernstein et al. [16] 2001 Canada Manitoba C.R. 19/2672 8438/1,151,000 0.97 0.62–1.52
Winther et al. [17] 2004 Denmark Copenhagen P.B.C. 4/1160 2598/557,500 0.74 0.28–1.94
Hemminki et al. [18] 2008 Sweden Sweden C.R. 277/27,606 79,005/8,976,000 1.14 1.01–1.28
Jussila et al. [13] 2013 Finland Finland C.R. 150/16,649 56,718/5,351,000 0.85 0.73–1.00
Kappelman et al. [10] 2014 Denmark Denmark C.R. 258/35,152 33,976/5,554,844 1.21 1.08–1.35
Wilson et al. [20] 2016 UK UK CPRD 62/11,797 51/11,797 1.21 0.84–1.76
Jung et al. [21] 2017 Korea Korea HIRA-d 18/9787 26,904/50,750,000 3.47 2.19–5.51
So et al. [22] 2017 H.K. H.K. IBD-d 8/1603 14,936/7,392,000 2.47 1.24–4.93
UK: United Kingdom; H.K.: Hong Kong; C.R.: cancer register; P.B.C.: population-based cohort; CPRD: clinical
practice research Datalink; HIRA-d: Health Insurance and Review Agency database; IBD: inflammatory bowel
disease; n= number; PC: prostate cancer; UC: ulcerative colitis; RR: relative risk; CI: confidence intervals.
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3.5. Quality Subanalysis
When studies with lower quality, considering a NOS score ≥ 7 as a sign of high quality [25], were
excluded from the analysis, the results previously described were co fir e , ith an increased R for
PC in patients with IBD, but with a non-statis ically releva t rease in risk for PC both in patients
with CD and UC (Supplem ntary Figure S1).
4. Discussion
Several meta-analyses and population studies have shown that IBD could be complicated by
intestinal cancers and some studies even provided evidence of an increased risk of some extra-intestinal
cancers, such as cholangiocarcinoma or hematological malignancies.
In the literature, there are only few studies examining the risk for PC in patients with IBD,
and the relationship between IBD and PC is still controversial. In fact, while some studies showed
an increased risk for PC in patients with IBD [12,21], others did not show any correlation between
these conditions [13,16].
Recently, two meta-analyses were published by Ge et al. and Chen et al., regarding the risk of
PC in IBD patients [26,27]. Ge et al. described a significantly increased risk of PC in patients with
IBD (SIR 1.33; 95%IC 1.03–1.71), confirmed in those with UC (SIR 1.58; 95%IC 1.08–2.30), but not in
patients with CD (SIR 1.12; 95%IC 0.97–1.31). Chen et al., on the other hand, described, in addition to
an increased risk for PC in IBD (RR/OR 1.78; 95%IC 1.32–2.41) and UC (OR/RR 1.76; 95%IC 1.06–2.91),
also a greater risk for PC in patients with CD (RR/OR 1.29; 95%IC 1.06–2.91).
Our meta-analysis showed a slightly different result: in fact, while we confirmed an increased
risk of PC in IBD patients (RR 1.71; 95%IC 1.16–2.51, p = 0.007), we did not evidence a statistically
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significant increased risk of PC in both UC (RR 1.22; 95%IC 0.98–1.51, p = 0.07) and CD (RR 1.10; 95%IC
0.98–1.25, p = 0.116). The difference can be explained by the fact that we included the highest number
of studies in our analysis. For instance, five studies included in our meta-analysis were absent from
the meta-analyses performed by Chen et al. [27] (three on UC and CD; two on UC) and four studies
were not included by Ge et al. [26] (two on UC and CD, two on UC). Furthermore, we excluded the
study by Jess et al. that was instead included by the other meta-analyses, because it did not satisfy our
inclusion criteria; in particular, the exact number of PC developed in the population with IBD was not
reported. The three meta-analyses had different designs: for example, when assessing the risk of PC in
patients with IBD, we considered only studies which included patients with both CD and UC, while
both Ge et al. and Chen et al., also included studies which considered only patients with UC or CD.
Overall, we found that patients with IBD had an increased risk of PC, but subgroup analysis
revealed that patients with UC or CD did not have any significant association with PC. Several reasons
can explain this contradiction. Regarding UC, the studies that did not show an increased risk of PC had
a smaller sample size, and consequently, they were more likely to be subject to beta error. In addition,
we included studies from various nations, referring to different populations, with highly dissimilar
characteristics. For instance, the higher RR for PC in the Asian studies could be due to the lower
incidence of PC in the population: in fact, even a small increase in the number of PC in patients with
IBD may give a high increase of the RR for PC in these populations.
Some limitations of the present study are: in the analysis, we did not consider some confounders,
that may influence the risk and the incidence of PC, such as family history of PC, screening programs
for PC through prostate-specific antigen (PSA), or the fact that the IBD patients could have an increased
ascertainment of PC because they are more frequently subjected to rectal examinations due to the
characteristics of the disease. Furthermore, we did not consider concomitant medications, such as
immunosuppressive drugs, that could increase the risk of developing cancer, decrease ability to
eradicate infections, and induce direct DNA impairment. Furthermore, there was a high heterogeneity
among the studies, probably due to the different age of the participants and follow-up periods. Another
possible bias could be the age of the patients of the included studies. Generally, the majority of
those affected by PC are older men, whereas UC and CD affect a younger population. Despite that,
the included studies matched case and control for age and showed also an SIR (standardized incidence
ratio): hence, this possible confounder was eliminated.
Importantly, our meta-analysis included the highest number of studies published on this subject;
we enrolled not only cohort studies, but even case-control ones, and we did a sub-analysis, excluding
studies with lower quality, thus confirming the obtained results.
5. Conclusions
Our study found that men with IBD have an increased risk of PC, but larger studies are needed to
evaluate the risk in the IBD subgroups, especially in patients with UC. Further research should aim at
evaluating the impact of concomitant medications on the risk of developing PC. These results could be
useful in evaluating the possibility of implementing tailored screening programs for PC in patients
with IBD.
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